The Latin America, Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Market is expected to witness market growth of 7.3% CAGR during the forecast period (2022-2028).
The rise in the prevalence of cardiovascular illnesses, the increased risk of organ failure, and the development of innovative congestive heart failure treatment devices by a significant number of heart failure device businesses are driving the CHF treatment devices market. A considerable number of people all over the world require a heart transplant after a certain age. As a result, the rising number of patients with heart failure has raised the demand for ventricular assist devices, which is expected to fuel market expansion and provide opportunities for congestive heart failure treatment devices.
Furthermore, an increase in the geriatric population has raised the number of cardiovascular disease patients, and a shortage of organ donors is one of the main factors driving growth in the congestive heart failure treatment devices market. The market is expected to develop as the burden of cardiovascular illnesses rises and the prevalence of heart failure increases. Additionally, the growing number of product approvals is likely to give lucrative prospects for the congestive heart failure therapy devices market players.
In the United Arab Emirates (UAE), cardiovascular disease was the main cause of death among women in 2010. Because heart attacks are more common in older women, indications of heart disease may be concealed by symptoms of chronic conditions, which could explain why women delay seeking medical help and have a greater death rate after an ischemic incident. There were various research and development programs across the region in order to raise awareness of heart disease among Emirati women and to better understand how Emirati women seek healthcare in the UAE. Cardiovascular diseases (CVD) kill more people in this region than any other disease, as per the World Health Organization. Moreover, the prevalence of CVDs are also very high among adult women as a considerable number of adult women across this region died from CVD in recent years.
The Brazil market dominated the LAMEA Congestive Heart Failure (CHF) Treatment Devices Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $294.5 Million by 2028. The Argentina market is poised to grow at a CAGR of 7.9% during (2022 - 2028). Additionally, The UAE market is expected to display a CAGR of 7% during (2022 - 2028).
Based on Product Type, the market is segmented into Pacemakers, Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy, and Ventricular Assist Devices. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, MicroPort Scientific Corporation, Abbott Laboratories, Medtronic PLC, Abiomed, Inc., Berlin Heart GmbH, Jarvik Heart, Inc., Lepu Medical Technology (Beijing) Co., Ltd., BIOTRONIK SE & Co. KG, and Osypka Medical GmbH.
The rise in the prevalence of cardiovascular illnesses, the increased risk of organ failure, and the development of innovative congestive heart failure treatment devices by a significant number of heart failure device businesses are driving the CHF treatment devices market. A considerable number of people all over the world require a heart transplant after a certain age. As a result, the rising number of patients with heart failure has raised the demand for ventricular assist devices, which is expected to fuel market expansion and provide opportunities for congestive heart failure treatment devices.
Furthermore, an increase in the geriatric population has raised the number of cardiovascular disease patients, and a shortage of organ donors is one of the main factors driving growth in the congestive heart failure treatment devices market. The market is expected to develop as the burden of cardiovascular illnesses rises and the prevalence of heart failure increases. Additionally, the growing number of product approvals is likely to give lucrative prospects for the congestive heart failure therapy devices market players.
In the United Arab Emirates (UAE), cardiovascular disease was the main cause of death among women in 2010. Because heart attacks are more common in older women, indications of heart disease may be concealed by symptoms of chronic conditions, which could explain why women delay seeking medical help and have a greater death rate after an ischemic incident. There were various research and development programs across the region in order to raise awareness of heart disease among Emirati women and to better understand how Emirati women seek healthcare in the UAE. Cardiovascular diseases (CVD) kill more people in this region than any other disease, as per the World Health Organization. Moreover, the prevalence of CVDs are also very high among adult women as a considerable number of adult women across this region died from CVD in recent years.
The Brazil market dominated the LAMEA Congestive Heart Failure (CHF) Treatment Devices Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $294.5 Million by 2028. The Argentina market is poised to grow at a CAGR of 7.9% during (2022 - 2028). Additionally, The UAE market is expected to display a CAGR of 7% during (2022 - 2028).
Based on Product Type, the market is segmented into Pacemakers, Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy, and Ventricular Assist Devices. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, MicroPort Scientific Corporation, Abbott Laboratories, Medtronic PLC, Abiomed, Inc., Berlin Heart GmbH, Jarvik Heart, Inc., Lepu Medical Technology (Beijing) Co., Ltd., BIOTRONIK SE & Co. KG, and Osypka Medical GmbH.
Scope of the Study
Market Segments Covered in the Report:
By Product Type
- Pacemakers
- Implantable Cardioverter Defibrillators
- Cardiac Resynchronization Therapy
- Ventricular Assist Devices
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Boston Scientific Corporation
- MicroPort Scientific Corporation
- Abbott Laboratories
- Medtronic PLC
- Abiomed, Inc.
- Berlin Heart GmbH
- Jarvik Heart, Inc.
- Lepu Medical Technology (Beijing) Co., Ltd.
- BIOTRONIK SE & Co. KG
- Osypka Medical GmbH
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Congestive Heart Failure (CHF) Treatment Devices Market by Product Type
Chapter 5. LAMEA Congestive Heart Failure (CHF) Treatment Devices Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- MicroPort Scientific Corporation
- Abbott Laboratories
- Medtronic PLC
- Abiomed, Inc.
- Berlin Heart GmbH
- Jarvik Heart, Inc.
- Lepu Medical Technology (Beijing) Co., Ltd.
- BIOTRONIK SE & Co. KG
- Osypka Medical GmbH
Methodology
LOADING...
